These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17965366)

  • 21. Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
    An MM; Zou Z; Shen H; Zhang JD; Chen ML; Liu P; Wang R; Jiang YY
    BMC Infect Dis; 2009 Dec; 9():193. PubMed ID: 19951447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
    Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
    Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.
    Stearne LE; van Boxtel D; Lemmens N; Goessens WH; Mouton JW; Gyssens IC
    Antimicrob Agents Chemother; 2004 May; 48(5):1688-98. PubMed ID: 15105122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
    Jansen JP; Kumar R; Carmeli Y
    Pharmacoeconomics; 2009; 27(12):1045-56. PubMed ID: 19908928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
    Xu ZR; Ran XW; Xian Y; Yan XD; Yuan GY; Mu SM; Shen JF; Zhang BS; Gan WJ; Wang J
    J Antimicrob Chemother; 2016 Jun; 71(6):1688-96. PubMed ID: 26888908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.
    Beale AS; Gisby J
    Infection; 1991; 19(2):101-5. PubMed ID: 2050417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.
    Kern W; Kennedy SL; Sachdeva M; Sande ER; Gunderson D; Täuber MG
    Antimicrob Agents Chemother; 1990 May; 34(5):697-701. PubMed ID: 2163241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
    Fujita A; Kimura K; Yokoyama S; Jin W; Wachino J; Yamada K; Suematsu H; Yamagishi Y; Mikamo H; Arakawa Y
    PLoS One; 2015; 10(11):e0142366. PubMed ID: 26539828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q; Rand K; Derendorf H
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
    Brook I
    Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.
    Tan JS; Wishnow RM; Talan DA; Duncanson FP; Norden CW
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1580-6. PubMed ID: 8215266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
    Gesser RM; McCarroll K; Teppler H; Woods GL
    J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
    Monogue ML; Nicolau DP
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7527-7529. PubMed ID: 27799205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
    Wells CL; Arland LA; Simmons RL; Rotstein OD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
    Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell KL; Gesser RM
    Clin Infect Dis; 2002 Sep; 35(Suppl 1):S119-25. PubMed ID: 12173120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
    Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
    J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.